首页> 外文期刊>Tumour biology : >Normalizers for microRNA quantification in plasma of patients with vulvar intraepithelial neoplasia lesions and vulvar carcinoma
【24h】

Normalizers for microRNA quantification in plasma of patients with vulvar intraepithelial neoplasia lesions and vulvar carcinoma

机译:外阴上皮内瘤样病变和外阴癌患者血浆中microRNA定量的标准化试剂

获取原文
           

摘要

The role of circulating microRNAs as a promising tool for diagnosing cancer and monitoring anticancer therapies has been widely studied in the past decades. To date, no suitable reference microRNAs for normalizing quantitative real-time polymerase chain reaction assays has been identified in vulvar intraepithelial neoplasia lesions and vulvar squamous cell carcinoma. The purpose of this study was to select appropriate references for gene expression studies in plasma of patients with these lesions. Expression levels of six microRNAs—hsa-miR-425-5p, hsa-miR-191-5p, hsa-miR-93-5p, hsa-miR-423-5p, hsa-miR-103a-3p, and hsa-miR-16-5p—were analyzed by quantitative reverse transcription polymerase chain reaction in plasma samples obtained from 17 patients with vulvar intraepithelial neoplasia lesion and 27 patients with vulvar squamous cell carcinoma. The expression stability of these candidate normalizers was assayed using geNorm algorithm. hsa-miR-93-5p was revealed as the most stably expressed reference in plasma samples of both vulvar intraepithelial neoplasia lesion and vulvar squamous cell carcinoma patients. The results pointed at hsa-miR-93-5p and hsa-miR-425-5p as microRNAs that retained the greatest robustness in plasma of vulvar intraepithelial neoplasia lesion and vulvar squamous cell carcinoma patients, respectively. Our work is the first report on reference microRNA selection for quantitative real-time polymerase chain reaction applications in vulvar intraepithelial neoplasia lesion and vulvar squamous cell carcinoma. The candidate microRNA stability values for the two types of lesions are provided and might serve for normalization of the future novel microRNA biomarkers in these rare entities.
机译:在过去的几十年中,循环microRNA作为诊断癌症和监测抗癌治疗的有前途工具的作用已得到广泛研究。迄今为止,尚未在外阴上皮内瘤变病变和外阴鳞状细胞癌中鉴定出合适的用于标准化实时定量聚合酶链反应测定的参考微RNA。这项研究的目的是为患有这些病变的患者的血浆中的基因表达研究选择合适的参考。六个microRNA的表达水平-hsa-miR-425-5p,hsa-miR-191-5p,hsa-miR-93-5p,hsa-miR-423-5p,hsa-miR-103a-3p和hsa-miR通过定量逆转录聚合酶链反应分析从17例外阴上皮内瘤样病变和27例外阴鳞状细胞癌患者的血浆样本中分析了-16-5p。使用geNorm算法分析了这些候选标准化基因的表达稳定性。在外阴上皮内瘤变病变和外阴鳞状细胞癌患者的血浆样品中,hsa-miR-93-5p被揭示为最稳定表达的参考。结果指出,hsa-miR-93-5p和hsa-miR-425-5p分别是在外阴上皮内瘤样病变和外阴鳞状细胞癌患者血浆中保持最大稳健性的microRNA。我们的工作是有关用于外阴上皮内瘤变病变和外阴鳞状细胞癌实时定量聚合酶链反应应用的参考microRNA选择的第一份报告。提供了两种类型病变的候选microRNA稳定性值,这些值可能有助于这些罕见实体中未来新型microRNA生物标记物的标准化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号